Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Dennis A. Eichenauer, Indra Thielen, Heinz Haverkamp, Jeremy Franklin, Karolin Behringer, Teresa Halbsguth, Beate Klimm, Volker Diehl, Stephanie Sasse, Achim Rothe, Michael Fuchs, Boris Böll, Bastian von Tresckow, Peter Borchmann, Andreas Engert

Blood (2014) 123 (11): 1658–1664.

https://doi.org/10.1182/blood-2013-07-512657

Published: 2014

Includes: Supplemental data

Journal Articles

Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Blood (2012) 120 (21): 2636.

https://doi.org/10.1182/blood.V120.21.2636.2636

Published: 2012

Journal Articles

Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients

Michaela Rancea, Andreas Engert, MD, Peter Borchmann, MD, Bastian von Tresckow, MD, Teresa Halbsguth, MD, Karolin Behringer, MD, Diana Wongso, MD, Boris Böll, MD, Beate Klimm, MD, Indra Thielen, MD, Dennis A. Eichenauer, MD, Nicole Skoetz, MD

Blood (2012) 120 (21): 4230.

https://doi.org/10.1182/blood.V120.21.4230.4230

Published: 2012

Journal Articles

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Boris Böll, Henning Bredenfeld, Helen Görgen, Teresa Halbsguth, Hans T. Eich, Martin Soekler, Jana Markova, Ulrich Keller, Ullrich Graeven, Stephan Kremers, Michael Geissler, Guido Trenn, Michael Fuchs, Bastian von Tresckow, Dennis A. Eichenauer, Peter Borchmann, Andreas Engert

Blood (2011) 118 (24): 6292–6298.

https://doi.org/10.1182/blood-2011-07-368167

Published: 2011

Journal Articles

Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Michael Fuchs, MD, Annette Pluetschow, Beate Klimm, MD, Teresa Halbsguth, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2011) 118 (21): 2711.

https://doi.org/10.1182/blood.V118.21.2711.2711

Published: 2011

Journal Articles

Fertility and Gonadal Function After Treatment of Early Unfavorable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG)

Karolin Behringer, MD, Indra Thielen, MD, Horst Mueller, Helen Goergen, Angelika Eibl, Johannes Rosenbrock, Teresa Halbsguth, MD, Katrin S. Reiners, PhD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2011) 118 (21): 432.

https://doi.org/10.1182/blood.V118.21.432.432

Published: 2011

Journal Articles

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

Dennis A. Eichenauer, Michael Fuchs, Annette Pluetschow, Beate Klimm, Teresa Halbsguth, Boris Böll, Bastian von Tresckow, Lucia Nogová, Peter Borchmann, Andreas Engert

Blood (2011) 118 (16): 4363–4365.

https://doi.org/10.1182/blood-2011-06-361055

Published: 2011

Journal Articles

Secondary MDS/AML In Hodgkin Lymphoma Patients Treated within German Hodgkin Study Group (GHSG) Clinical Trials After Introduction of the BEACOPP Protocol

Dennis A. Eichenauer, Heinz Haverkamp, Karolin Behringer, Teresa Halbsguth, MD, Michael Fuchs, Volker Diehl, Peter Borchmann, Andreas Engert

Blood (2010) 116 (21): 2682.

https://doi.org/10.1182/blood.V116.21.2682.2682

Published: 2010

Journal Articles

Longitudinal Evaluation of Quality of Life and Fatigue In Hodgkin Lymphoma Patients

Peter Borchmann, MD, Horst Müller, Corinne Brillant, Karolin Behringer, Teresa Halbsguth, MD, Volker Diehl, Hans Henning Flechtner, Andreas Engert, MD

Blood (2010) 116 (21): 935.

https://doi.org/10.1182/blood.V116.21.935.935

Published: 2010

Journal Articles

PVAG (Prednisone, Vinblastine, Doxorubicin and Gemcitabine) In Elderly Patients with Intermediate or Advanced Stage Hodgkin Lymphoma: Final Results of a Phase II Study of the German Hodgkin Study Group (GHSG).

Boris Böll, MD, Teresa Halbsguth, MD, Helen Görgen, Henning Bredenfeld, MD, Hans Eich, Michael Fuchs, Peter Borchmann, MD, Andreas Engert, MD

Blood (2010) 116 (21): 2827.

https://doi.org/10.1182/blood.V116.21.2827.2827

Published: 2010

Journal Articles

“Quality of Life (QoL) in the Randomised HD10-12 Trials of the German Hodgkin Study Group (GHSG): Sexual Functions (SX) in Hodgkin Lymphoma (HL) Patients Decrease by Disease Stage and Improve After Therapy Depending On Stage and Treatment Modality.”.

Karolin Behringer, Horst Mueller, Hans-Henning Flechtner, Corinne Brillant, Teresa Halbsguth, Thomas Schober, Hiltrud Nisters-Backes, Andreas Engert, MD, Peter Borchmann

Blood (2009) 114 (22): 896.

https://doi.org/10.1182/blood.V114.22.896.896

Published: 2009

Journal Articles

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Horst Mueller, Lucia Nogova, Dennis A Eichenauer, Teresa Halbsguth, Hiltrud Nisters-Backes, Thomas Schober, Hartmut Eimermacher, Peter Borchmann, Michael Fuchs, Andreas Engert, Andreas Josting

Blood (2008) 112 (11): 2600.

https://doi.org/10.1182/blood.V112.11.2600.2600

Published: 2008

Journal Articles

Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10–12 Trials of the German Hodgkin Study Group (GHSG).

Teresa Halbsguth, Horst Mueller, Hans-Henning Flechtner, Corinne Brillant, Karolin Behringer, Thomas Schober, Hiltrud Nisters-Backes, Andreas Engert, Peter Borchmann

Blood (2008) 112 (11): 1455.

https://doi.org/10.1182/blood.V112.11.1455.1455

Published: 2008

NARROW

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)

Fertility and Gonadal Function After Treatment of Early Unfavorable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG)

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

Secondary MDS/AML In Hodgkin Lymphoma Patients Treated within German Hodgkin Study Group (GHSG) Clinical Trials After Introduction of the BEACOPP Protocol

Longitudinal Evaluation of Quality of Life and Fatigue In Hodgkin Lymphoma Patients

PVAG (Prednisone, Vinblastine, Doxorubicin and Gemcitabine) In Elderly Patients with Intermediate or Advanced Stage Hodgkin Lymphoma: Final Results of a Phase II Study of the German Hodgkin Study Group (GHSG).

“Quality of Life (QoL) in the Randomised HD10-12 Trials of the German Hodgkin Study Group (GHSG): Sexual Functions (SX) in Hodgkin Lymphoma (HL) Patients Decrease by Disease Stage and Improve After Therapy Depending On Stage and Treatment Modality.”.

The Newly Developed Modified BEACOPP-Regimen (BACOPP) Is Active and Feasible in Elderly Patients with Hodgkin Lymphoma: Results of a Phase II Study of the German Hodgkin Study Group (GHSG)

Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10–12 Trials of the German Hodgkin Study Group (GHSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only